IRIS publication 43335172
Evaluation of colostrum-derived human mammary-associated serum amyloid A3 (M-SAA3) protein and peptide derivatives for the prevention of enteric infection: in vitro and in murine models of intestinal disease
RIS format for Endnote and similar
TY - JOUR - Gardiner, GE,O'Flaherty, S,Casey, PG,Weber, A,McDonald, TL,Cronin, M,Hill, C,Ross, RP,Gahan, CGM,Shanahan, F - 2009 - April - Fems Immunology and Medical Microbiology - Evaluation of colostrum-derived human mammary-associated serum amyloid A3 (M-SAA3) protein and peptide derivatives for the prevention of enteric infection: in vitro and in murine models of intestinal disease - Validated - () - mammary associated serum amyloid A3 enteropathogenic Escherichia coli Salmonella infection mouse ENTEROPATHOGENIC ESCHERICHIA-COLI PORCINE GASTROINTESTINAL-TRACT CITROBACTER-RODENTIUM COLONIC HYPERPLASIA BOVINE-MILK MUC3 MUCIN EXPRESSION PROBIOTICS GROWTH MICE - 55 - 404 - 413 - In vitro experiments confirmed that a 10-mer peptide derived from human mammary-associated serum amyloid A3 (M-SAA3) protected intestinal epithelial cells from enteropathogenic Escherichia coli (EPEC) adherence. The entire 42-mer human M-SAA3 protein was even more effective, reducing EPEC binding by 72% relative to untreated cells (P < 0.05), compared with 25% and 57% reductions for the human 10-mer and Lactobacillus GG, respectively. However, none of the M-SAA3 peptides reduced Salmonella invasion in vitro (P > 0.05). Each of the M-SAA3 10-mer peptides and the 42-mer was then administered orally to mice at 500 mu g day(-1) for 4 days before deliberate infection with either Citrobacter rodentium (mouse model of EPEC) or Salmonella Typhimurium. None of the peptides protected against Salmonella infection and the 42-mer may even increase infection, as there was a trend towards increased Salmonella counts in the liver and small intestine in 42-mer-treated mice compared with those in sodium acetate-treated control mice. Citrobacter counts were reduced in the caecum of mice administered the 42-mer relative to a scrambled 10-mer (P < 0.05), but not compared with the sodium acetate control and no reductions were observed in the faeces or colon. Overall, although promising anti-infective activity was demonstrated in vitro, neither the 42-mer M-SAA3 protein nor a 10-mer peptide derivative prevented enteric infection in the animal models tested. - DOI 10.1111/j.1574-695X.2009.00539.x DA - 2009/04 ER -
BIBTeX format for JabRef and similar
@article{V43335172, = {Gardiner, GE and O'Flaherty, S and Casey, PG and Weber, A and McDonald, TL and Cronin, M and Hill, C and Ross, RP and Gahan, CGM and Shanahan, F }, = {2009}, = {April}, = {Fems Immunology and Medical Microbiology}, = {Evaluation of colostrum-derived human mammary-associated serum amyloid A3 (M-SAA3) protein and peptide derivatives for the prevention of enteric infection: in vitro and in murine models of intestinal disease}, = {Validated}, = {()}, = {mammary associated serum amyloid A3 enteropathogenic Escherichia coli Salmonella infection mouse ENTEROPATHOGENIC ESCHERICHIA-COLI PORCINE GASTROINTESTINAL-TRACT CITROBACTER-RODENTIUM COLONIC HYPERPLASIA BOVINE-MILK MUC3 MUCIN EXPRESSION PROBIOTICS GROWTH MICE}, = {55}, pages = {404--413}, = {{In vitro experiments confirmed that a 10-mer peptide derived from human mammary-associated serum amyloid A3 (M-SAA3) protected intestinal epithelial cells from enteropathogenic Escherichia coli (EPEC) adherence. The entire 42-mer human M-SAA3 protein was even more effective, reducing EPEC binding by 72% relative to untreated cells (P < 0.05), compared with 25% and 57% reductions for the human 10-mer and Lactobacillus GG, respectively. However, none of the M-SAA3 peptides reduced Salmonella invasion in vitro (P > 0.05). Each of the M-SAA3 10-mer peptides and the 42-mer was then administered orally to mice at 500 mu g day(-1) for 4 days before deliberate infection with either Citrobacter rodentium (mouse model of EPEC) or Salmonella Typhimurium. None of the peptides protected against Salmonella infection and the 42-mer may even increase infection, as there was a trend towards increased Salmonella counts in the liver and small intestine in 42-mer-treated mice compared with those in sodium acetate-treated control mice. Citrobacter counts were reduced in the caecum of mice administered the 42-mer relative to a scrambled 10-mer (P < 0.05), but not compared with the sodium acetate control and no reductions were observed in the faeces or colon. Overall, although promising anti-infective activity was demonstrated in vitro, neither the 42-mer M-SAA3 protein nor a 10-mer peptide derivative prevented enteric infection in the animal models tested.}}, = {DOI 10.1111/j.1574-695X.2009.00539.x}, source = {IRIS} }
Data as stored in IRIS
AUTHORS | Gardiner, GE,O'Flaherty, S,Casey, PG,Weber, A,McDonald, TL,Cronin, M,Hill, C,Ross, RP,Gahan, CGM,Shanahan, F | ||
YEAR | 2009 | ||
MONTH | April | ||
JOURNAL_CODE | Fems Immunology and Medical Microbiology | ||
TITLE | Evaluation of colostrum-derived human mammary-associated serum amyloid A3 (M-SAA3) protein and peptide derivatives for the prevention of enteric infection: in vitro and in murine models of intestinal disease | ||
STATUS | Validated | ||
TIMES_CITED | () | ||
SEARCH_KEYWORD | mammary associated serum amyloid A3 enteropathogenic Escherichia coli Salmonella infection mouse ENTEROPATHOGENIC ESCHERICHIA-COLI PORCINE GASTROINTESTINAL-TRACT CITROBACTER-RODENTIUM COLONIC HYPERPLASIA BOVINE-MILK MUC3 MUCIN EXPRESSION PROBIOTICS GROWTH MICE | ||
VOLUME | 55 | ||
ISSUE | |||
START_PAGE | 404 | ||
END_PAGE | 413 | ||
ABSTRACT | In vitro experiments confirmed that a 10-mer peptide derived from human mammary-associated serum amyloid A3 (M-SAA3) protected intestinal epithelial cells from enteropathogenic Escherichia coli (EPEC) adherence. The entire 42-mer human M-SAA3 protein was even more effective, reducing EPEC binding by 72% relative to untreated cells (P < 0.05), compared with 25% and 57% reductions for the human 10-mer and Lactobacillus GG, respectively. However, none of the M-SAA3 peptides reduced Salmonella invasion in vitro (P > 0.05). Each of the M-SAA3 10-mer peptides and the 42-mer was then administered orally to mice at 500 mu g day(-1) for 4 days before deliberate infection with either Citrobacter rodentium (mouse model of EPEC) or Salmonella Typhimurium. None of the peptides protected against Salmonella infection and the 42-mer may even increase infection, as there was a trend towards increased Salmonella counts in the liver and small intestine in 42-mer-treated mice compared with those in sodium acetate-treated control mice. Citrobacter counts were reduced in the caecum of mice administered the 42-mer relative to a scrambled 10-mer (P < 0.05), but not compared with the sodium acetate control and no reductions were observed in the faeces or colon. Overall, although promising anti-infective activity was demonstrated in vitro, neither the 42-mer M-SAA3 protein nor a 10-mer peptide derivative prevented enteric infection in the animal models tested. | ||
PUBLISHER_LOCATION | |||
ISBN_ISSN | |||
EDITION | |||
URL | |||
DOI_LINK | DOI 10.1111/j.1574-695X.2009.00539.x | ||
FUNDING_BODY | |||
GRANT_DETAILS |